NEW YORK, February 9, 2017 /PRNewswire/ --
Focus is back on the Biotech industry which was one of the weakest performersin the stock market in 2016, declining over 21% as represented by the iShares Nasdaq Biotechnology ETF. According to an article on Seeking Alpha, signs that the sector would potentially breakout this year are present, and M&A deals can also catalyze
Tarrytown, New York-based Progenics Pharmaceuticals Inc.'s shares gained 0.52%, closing Wednesday's trading session at $9.58. The stock recorded a trading volume of 569,259 shares. The Company's shares have advanced 9.61% in the last month, 75.78% in the previous three months, and 10.88% on an YTD basis. The stock is trading 7.11% above its 50-day moving average and 46.37% above its 200-day moving average. Additionally, shares of Progenics Pharma, which develops medicines for oncology in the US and internationally, have a Relative Strength Index (RSI) of 59.05. On December 22nd, 2016, Progenics Pharmaceuticals announced that its independent Data Monitoring Committee (DMC) has completed review of an interim analysis of the Company's ongoing Phase 3 clinical trial of its PSMA-targeted SPECT/CT imaging agent candidate, 99mTc-MIP-1404 (1404), and recommended that the trial continue.
On February 06th, 2017, research firm Needham upgraded the Company's stock rating from 'Buy' to 'Strong Buy' while revising its previous target price from $11 a share to $14 a share. See our free and comprehensive research report on PGNX at:
On Wednesday, shares in Germantown, Maryland-based Intrexon Corp. recorded a trading volume of 1.01 million shares. The stock declined 0.37%, ending the day at $21.33. The Company's shares are trading below their 50-day moving average by 17.12%. Furthermore, shares of Intrexon, which operates in the synthetic biology field in the US, have an RSI of 34.63.
On January 24th, 2017, Intrexon announced that it has entered into a definitive agreement to acquire GenVec, Inc., a clinical-stage company and pioneer in the development of AdenoVerse™ gene delivery technology. Pursuant to the definitive agreement, upon the closing of the transaction GenVec stockholders will receive 0.297 of a share of Intrexon's Common Stock in exchange for each share of GenVec's common stock. GenVec's stockholders will also receive a right to contingent consideration equal to 50% of any milestone or royalty payments received within 36 months after the closing of the transaction under GenVec's Research Collaboration and License Agreement with Novartis. Consummation of the acquisition is subject to customary closing conditions, including GenVec's stockholder approval, and is expected to occur in Q2 2017. XON free research report PDF is just a click away at:
Rockville, Maryland headquartered Synthetics Biologics Inc.'s stock finished the day 2.84% lower at $0.83 with a total trading volume of 489,139 shares. The Company's shares have gained 8.84% since the start of this year. The stock is trading below its 50-day moving average by 1.19%. Additionally, shares of Synthetics Biologics, which engages in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases in the US, have an RSI of 47.97.
On January 18th, 2017, Synthetic Biologics confirmed plans to initiate a Phase 2b/3 adaptive pivotal trial for SYN-010, the Company's modified-release reformulation of lovastatin lactone designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat the underlying cause of irritable bowel syndrome with constipation. The Company anticipates initiating this trial by the end of Q1 2017. Sign up for your complimentary report on SYN at:
Shares in Clarence, New York headquartered 22nd Century Group Inc. ended yesterday's session 2.22% lower at $0.88. The stock recorded a trading volume of 320,457 shares. The Company's shares have advanced 1.59% in the last one month. The stock is trading 9.70% below its 50-day moving average. Moreover, shares of 22nd Century Group, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 38.72.
On February 03rd, 2017, 22nd Century announced that the Company prevailed again in the most recent phase of the lawsuit filed by Crede CG III, Ltd. Crede filed the lawsuit after the Company terminated its failed China joint venture arrangement with Crede and its principal, Terren Peizer, due to non-performance and other serious breaches by Crede and its principals. Register for free on Stock-Callers.com and download the latest research report on XXII at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All